New serological markers in inflammatory bowel disease are associated with complicated disease behaviour - Wikidata - awgldk - TriplyDB

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

http://www.wikidata.org/entity/Q22242048

about

Inflammatory bowel disease in Asia: A systematic review Novel Anti-Glycan Antibodies Related to Inflammatory Bowel Disease Diagnosis and Phenotype Novel biomarkers of fibrosis in Crohn's disease Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease Antibody markers in the diagnosis of inflammatory bowel disease Autoantibodies and an immune-based rat model of inflammatory bowel disease Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives Characterization of changes in serum anti-glycan antibodies in Crohn's disease--a longitudinal analysis Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?Seroreactivity against glycolytic enzymes in inflammatory bowel disease.Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.Is the disease course predictable in inflammatory bowel diseases?Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.New proteomic approaches for biomarker discovery in inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?Serum anti-glycan antibodies in paediatric-onset Crohn's disease: association with disease phenotype and diagnostic accuracy.Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.Mycobiota in gastrointestinal diseases.Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.Characterization of the gut-associated microbiome in inflammatory pouch complications following ileal pouch-anal anastomosis Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease Current and future role of biomarkers in Crohn's disease risk assessment and treatment.ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice.Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.Predictors of aggressive inflammatory bowel disease.Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases.Biomarkers in inflammatory bowel disease: current practices and recent advances.Distinct Microbiotas are Associated with Ileum-Restricted and Colon-Involving Crohn's Disease.Anticommensal Responses Are Associated with Regulatory T Cell Defect in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Patients.Increased levels of anti-glycan antibodies in patients with cystic fibrosis.Pediatric inflammatory bowel disease with cytoplasmic staining of antineutrophil cytoplasmic antibodies Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases.Elastic scattering spectroscopy as an optical marker of inflammatory bowel disease activity and subtypes.Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan.Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease.Current understanding of fungal microflora in inflammatory bowel disease pathogenesis

P2860

Q22242420-AC6BF43E-2807-4510-BC1E-9856EA903ABC Q22251117-421BEA8A-383F-4D47-93EF-78E500B8EE2A Q26738287-9E0057CB-6B09-4850-ADA8-0BB8AF3FAB26 Q26768273-A506D40B-17B1-4229-A90F-BE0183655BB0 Q26774452-D4A7E418-24C0-47B6-A30E-3CC13595A8FA Q26822756-AF2DA832-E0A0-4319-A31E-2F3FFB4EDBEA Q27000411-04F3436F-1982-41A0-A02A-BA83FBEE28D3 Q28085134-CF44365E-7BF1-463B-85BE-8089A7AFA24E Q28740412-6C771700-2B53-4AA3-87BE-B709479A35F9 Q30242073-B6632C21-C036-4BE3-8482-DFFB91D0C893 Q33632430-DD545F34-4417-4010-A1C7-CDB00FE9A9C5 Q33718699-AE07227A-15B5-4E9C-98D9-92598981818E Q33761406-3037A180-FE8C-480A-B45D-3CBBCD2FC277 Q33894191-49C91E54-1A2B-43BE-9630-D8FE41586AC9 Q33894195-223C5669-EE4E-490E-8A3D-3A20D7BC1B64 Q34096526-F7CA5ABF-7CAE-4A0A-A3C4-DF5C28E5C0FF Q34147687-C6F4CF24-2B71-4168-88EB-067CACCD66B9 Q34258150-91D9791D-81C0-4B33-BDD9-A533A12266BB Q34367414-82409B4C-0B59-49FF-8A4F-EB6C120501F1 Q34388523-5F6FA4D6-9A4E-4B83-80E7-3AF98F37FBAC Q34447163-5D34F7A1-FF87-4C13-86D2-152BBF3FC467 Q34976051-27A689CA-484F-4EEF-8C61-BC4C43E5B462 Q35004592-3C77B0E6-BD24-4767-A15B-0F0E43174B2E Q35058495-ECEBAD1E-4CF4-4925-B9A2-22E81622C7F0 Q35095265-B92CC17D-D54D-43E5-9F0E-4F95E7528A00 Q35210622-B49B0F8F-C4C6-4913-A1F1-BEEE3AC688E8 Q35381299-798A8FCC-1063-438E-94A4-63BFAEF04EAE Q35691407-368E9293-EED4-4308-A1DF-A908A67185A1 Q35748693-A53CD887-F388-4E09-8A23-5AAD6CA99A4A Q35755268-F272B28F-E369-4416-8C57-F15BCF35FB9A Q35840853-883F1399-34D1-4EAF-B077-70C30B9CC3E2 Q35890578-09BEF3A4-F27E-4DE3-976A-D43AEB1653EE Q35931810-D9D37F87-B31F-4C59-9376-91A19A583071 Q35959693-AE6EA5F6-48B3-4C76-8956-8548E62E976E Q36651184-95A943EB-6702-423F-B73E-948890B42A4C Q36702482-F2752159-CA85-4EEE-A0C1-CCBFF77142C0 Q36874416-19E1A841-198B-49B4-9F0E-32A609099171 Q36994288-85785D78-EBF0-4ABB-BE53-EFDD1F817C15 Q37064590-59E1C92F-7333-4C36-865D-815E1499D7E3 Q37089171-ACC0EE03-DADC-4BD6-AF66-493DED147460

P2860

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

http://www.wikidata.org/entity/Q22242048

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

New serological markers in inf ...... complicated disease behaviour

@ast

New serological markers in inf ...... complicated disease behaviour

@en

New serological markers in inf ...... complicated disease behaviour

@en-gb

New serological markers in inf ...... complicated disease behaviour

@nl

type

label

New serological markers in inf ...... complicated disease behaviour

@ast

New serological markers in inf ...... complicated disease behaviour

@en

New serological markers in inf ...... complicated disease behaviour

@en-gb

New serological markers in inf ...... complicated disease behaviour

@nl

prefLabel

New serological markers in inf ...... complicated disease behaviour

@ast

New serological markers in inf ...... complicated disease behaviour

@en

New serological markers in inf ...... complicated disease behaviour

@en-gb

New serological markers in inf ...... complicated disease behaviour

@nl

P1433

Q22242048-1EDF28CF-2986-4C7A-933D-11E4810E7F00

P1476

Q22242048-EF175BCE-887C-4DF4-8552-79C31B0D48B2

P2093

Q22242048-3798DDD2-6F39-435D-97C0-3C62B8D9644E

Q22242048-441A8E0B-C462-425C-BBC8-895C2873D668

Q22242048-47D77EE8-C46A-43E9-A54B-47BE56DF2478

Q22242048-6E1B150E-E6F2-4CF8-B58B-7182F8C67E5C

Q22242048-94A8D4EB-AAEB-4AF8-B759-0679500A727D

Q22242048-CD9CF260-3E61-41A5-BB70-56AE1728380F

Q22242048-EDD7927D-0246-415F-9CFF-7CBC34083544

P2860

Q22242048-027A4E53-5F45-4E7B-9FBB-B86C082C1314

Q22242048-05919B4C-4423-4700-856A-ED032C01D461

Q22242048-0D235097-0F7E-4152-B277-4D4E80DBD422

Q22242048-0EECFDAE-1696-40F3-AECD-91716B63DAD1

Q22242048-16257DBA-0ED6-4381-8BE5-A2CDFF1710E0

Q22242048-247BDE3C-3324-4F03-BCD2-7E2750F8A0AE

Q22242048-24C9E0CA-02CE-4EAE-94A5-397B19EA5F18

Q22242048-27608988-8A91-4C6B-AC63-78936404E5F1

Q22242048-2BB4F622-290C-49C7-ADBE-E55CC001D8F7

Q22242048-3C1CADCB-1FB1-4066-A5C0-A3D705BE2F7C

P304

Q22242048-EBBAA268-D37E-45D5-AE2D-DBCB600FC34D

P31

Q22242048-B10A8CB7-9636-41B0-B984-F6ED4723493F

P3181

Q22242048-6A316B9B-1F11-42BA-AB00-5B812BC027EE

P356

Q22242048-3AEC9DE2-E15E-4B7E-A2A7-3C91411B90D4

P407

Q22242048-ED71349B-7F3E-4E04-99B7-C77076574491

P433

Q22242048-BA1658AD-FFCE-4C8B-91EF-E9A222BC2A08

P478

Q22242048-E5B5E97C-4BC7-45B6-B4DE-EE6BCF4CA170

P50

Q22242048-1FF25945-88FE-40A9-BC97-B8DFD102EAB7

Q22242048-3BCD4B5A-6F29-426C-874E-4E72B593A2AA

Q22242048-48CB85B7-C7F5-43F0-A07B-60F729BBBD3A

Q22242048-B2E88231-A10D-4259-9827-99394F99B455

Q22242048-FD701F0B-00B5-4703-A5C4-553D74CBD21F

P577

Q22242048-2BF5D970-2693-4AE0-AE1B-2FD34ACEDF53

P5875

Q22242048-BFD116F1-E065-4865-A81C-16C2846C1E3D

P698

Q22242048-B83F2D9B-9B40-4661-9AE3-EDA90C9687FC

P921

Q22242048-03CC241F-0F48-438B-AAA6-ABF785BE06B5

Q22242048-07C66AF2-ED1D-4ACD-A0BF-2FEB394715A1

P932

Q22242048-9AC87FCE-959D-4852-A0F5-925A6C2265DB

P3181

P356

GUT.2006.108043

P1433

P1476

New serological markers in inf ...... complicated disease behaviour

@en

P2093

Gary L Norman

http://www.w3.org/2001/XMLSchema#string

Liesbet Henckaerts

http://www.w3.org/2001/XMLSchema#string

Marc Ferrante

http://www.w3.org/2001/XMLSchema#string

Marie Pierik

http://www.w3.org/2001/XMLSchema#string

Nir Dotan

http://www.w3.org/2001/XMLSchema#string

Rom T Altstock

http://www.w3.org/2001/XMLSchema#string

Sofie Joossens

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease

Specific antibody response to oligomannosidic epitopes in Crohn's disease

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

The value of serologic markers in indeterminate colitis: a prospective follow-up study

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Impact of cessation of smoking on the course of ulcerative colitis.

Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis.

Serologic markers in inflammatory bowel disease.

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

P304

1394-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

114997

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/GUT.2006.108043

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Séverine Vermeire

Gert Van Assche

Kristel Van Steen

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6371683

http://www.w3.org/2001/XMLSchema#string

P698

17456509

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

2000264

http://www.w3.org/2001/XMLSchema#string